Skip to main content
Skip to main content
ALC logo

Alcon Inc. (ALC)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Alcon Inc. (ALC) trades at $73.44 with AI Score 51/100 (Hold). Alcon Inc. is a global eye care leader, developing and selling a comprehensive suite of surgical and vision care products. Market cap: 36B, Sector: Healthcare.

Last analyzed: Feb 9, 2026
Alcon Inc. is a global eye care leader, developing and selling a comprehensive suite of surgical and vision care products. With a rich history of innovation, Alcon addresses diverse patient needs through its two core segments.
51/100 AI Score Target $91.80 (+25.0%) MCap 36B Vol 2M

Alcon Inc. (ALC) Healthcare & Pipeline Overview

CEODavid J. Endicott
Employees25599
HeadquartersGeneva, CH
IPO Year2019

Alcon Inc. pioneers eye care solutions, offering a comprehensive portfolio of surgical and vision care products, driving growth through innovation in intraocular lenses, contact lenses, and ocular health, while maintaining a strong market presence and a 10.3% profit margin.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 9, 2026

Investment Thesis

Alcon presents a notable research candidate driven by its leading position in the growing eye care market. With a market capitalization of $38.99 billion and a P/E ratio of 37.13, Alcon demonstrates financial stability and growth potential. The company's diverse product portfolio across surgical and vision care segments provides resilience and multiple avenues for expansion. Key value drivers include increasing demand for advanced technology IOLs, rising adoption of daily disposable contact lenses, and continued innovation in ocular health products. Upcoming catalysts include the launch of new IOL technologies and expansion into emerging markets. Alcon's commitment to R&D and its established brand reputation support a positive long-term outlook.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market Cap of $38.99B reflects Alcon's strong position in the eye care market.
  • P/E ratio of 37.13 indicates investor confidence in Alcon's earnings potential.
  • Gross Margin of 55.1% demonstrates efficient operations and strong pricing power.
  • Profit Margin of 10.3% highlights Alcon's ability to generate profits from its revenue.
  • Dividend Yield of 0.42% provides a steady income stream for investors.

Competitors & Peers

Strengths

  • Leading market position in both surgical and vision care.
  • Strong brand recognition and reputation.
  • Extensive product portfolio and global distribution network.
  • Commitment to research and development.

Weaknesses

  • Exposure to regulatory risks and product recalls.
  • Dependence on key products and technologies.
  • Competition from established and emerging players.
  • Potential for pricing pressure from healthcare providers and insurers.

Catalysts

  • Launch of new advanced technology IOLs for cataract surgery.
  • Expansion into new emerging markets in Asia and Latin America.
  • Increasing adoption of daily disposable contact lenses.
  • Growing demand for ocular health products due to aging population.
  • Continued innovation in surgical equipment and instrumentation.

Risks

  • Product recalls or safety concerns impacting brand reputation.
  • Changes in healthcare regulations affecting product approvals and reimbursement.
  • Competition from established and emerging players in the eye care market.
  • Economic downturns reducing consumer spending on vision care products.
  • Intellectual property infringement and patent disputes.

Growth Opportunities

  • Growth opportunity 1: Expanding the Advanced Technology IOL Portfolio: The global market for advanced technology IOLs is experiencing significant growth, driven by increasing patient demand for presbyopia and astigmatism correction during cataract surgery. Alcon's PanOptix and ReSTOR brands are well-positioned to capture a larger share of this market. By investing in R&D to develop even more advanced IOL designs and expanding its distribution network, Alcon can drive revenue growth in this high-margin segment. This market is estimated to reach $5 billion by 2028.
  • Growth opportunity 2: Increasing Penetration of Daily Disposable Contact Lenses: The daily disposable contact lens market is growing rapidly due to increased awareness of hygiene and convenience. Alcon's DAILIES AquaComfort PLUS lenses offer a compelling value proposition for consumers. By focusing on marketing and promotional activities to highlight the benefits of daily disposables, Alcon can drive increased adoption and market share. The global contact lens market is projected to reach $12 billion by 2027.
  • Growth opportunity 3: Expanding Ocular Health Product Offerings: The market for ocular health products, including dry eye treatments, glaucoma medications, and contact lens care solutions, is expanding due to an aging population and increased screen time. Alcon's TOTAL and OPTI-FREE brands are well-recognized and trusted by consumers. By investing in R&D to develop innovative new ocular health products and expanding its distribution channels, Alcon can capitalize on this growing market. The dry eye syndrome market alone is projected to reach $6 billion by 2025.
  • Growth opportunity 4: Entering Emerging Markets: Emerging markets, such as China, India, and Brazil, offer significant growth opportunities for Alcon due to their large populations and increasing healthcare spending. By establishing a strong presence in these markets through strategic partnerships and targeted marketing campaigns, Alcon can tap into a new customer base and drive revenue growth. These markets are experiencing rapid growth in demand for both surgical and vision care products.
  • Growth opportunity 5: Leveraging Digital Technologies: Alcon can leverage digital technologies, such as telemedicine and online ordering platforms, to enhance its customer reach and improve patient outcomes. By developing user-friendly digital tools and partnering with eye care professionals to integrate these technologies into their practices, Alcon can strengthen its competitive advantage and drive customer loyalty. This includes AI-powered diagnostic tools and personalized vision care solutions.

Opportunities

  • Expanding into emerging markets with high growth potential.
  • Developing innovative new products and technologies.
  • Leveraging digital technologies to enhance customer reach.
  • Acquiring complementary businesses to expand product offerings.

Threats

  • Economic downturns impacting healthcare spending.
  • Changes in healthcare regulations and reimbursement policies.
  • Technological disruptions from new entrants.
  • Product liability claims and litigation.

Competitive Advantages

  • Strong brand recognition and reputation in the eye care industry.
  • Extensive product portfolio covering both surgical and vision care needs.
  • Global distribution network reaching eye care professionals and patients worldwide.
  • Significant investment in research and development leading to innovative products.
  • Patents and intellectual property protecting key products and technologies.

About ALC

Founded in 1945 in Fort Worth, Texas, Alcon Inc. has evolved into a global leader in eye care. Initially a small pharmacy, the company specialized in ophthalmic products, quickly gaining recognition for its innovation and quality. Over the decades, Alcon expanded its product portfolio and geographic reach, establishing itself as a key player in both the surgical and vision care markets. Today, headquartered in Geneva, Switzerland, Alcon operates through two primary segments: Surgical and Vision Care. The Surgical segment provides equipment, instrumentation, intraocular lenses (IOLs), and consumables used in cataract, refractive, and vitreoretinal surgery. Key products include the Centurion Vision System, LenSx femtosecond laser, and a range of advanced technology IOLs like PanOptix and ReSTOR. The Vision Care segment offers a wide array of contact lenses, including daily disposable, reusable, and color-enhancing options, as well as ocular health products for dry eye, glaucoma, and contact lens care. Brands like TOTAL, PRECISION, DAILIES AquaComfort PLUS, and Air Optix are trusted by consumers worldwide. Alcon's commitment to research and development, coupled with its extensive distribution network, positions it as a dominant force in the global eye care industry, serving eye care professionals and patients in over 140 countries.

What They Do

  • Researches and develops eye care products.
  • Manufactures surgical equipment and instruments for eye surgeries.
  • Produces intraocular lenses (IOLs) for cataract and refractive surgery.
  • Offers a range of contact lenses, including daily disposable and reusable options.
  • Provides ocular health products for dry eye, glaucoma, and contact lens care.
  • Distributes its products to eye care professionals and patients worldwide.
  • Sells surgical consumables like viscoelastics and surgical solutions.

Business Model

  • Develops and manufactures a wide range of eye care products.
  • Sells products directly to eye care professionals and through distributors.
  • Generates revenue from both surgical and vision care segments.
  • Invests in research and development to innovate new products and technologies.

Industry Context

Alcon operates in the global eye care market, which is characterized by increasing prevalence of eye disorders, an aging population, and technological advancements. The market is highly competitive, with key players focusing on innovation and product differentiation. The surgical segment is driven by advancements in cataract and refractive surgery, while the vision care segment benefits from the growing demand for contact lenses and ocular health products. Alcon's extensive product portfolio and global presence position it favorably to capitalize on these trends. Competitors include companies like Becton Dickinson (BDX) and Cardinal Health (CAH), each vying for market share through different product offerings and geographic focuses.

Key Customers

  • Eye care professionals (ophthalmologists, optometrists, and surgeons)
  • Hospitals and surgical centers
  • Patients requiring vision correction or eye surgery
  • Retail consumers purchasing contact lenses and ocular health products
AI Confidence: 73% Updated: Feb 9, 2026

Financials

Chart & Info

Alcon Inc. (ALC) stock price: $73.44 (-1.56, -2.09%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALC.

Price Targets

Consensus target: $91.80

MoonshotScore

51/100

What does this score mean?

The MoonshotScore rates ALC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Common Questions About ALC (Healthcare)

What does Alcon Inc. do?

Alcon Inc. is a global leader in eye care, dedicated to helping people see brilliantly. The company researches, develops, manufactures, and sells a comprehensive suite of eye care products, divided into two main segments: Surgical and Vision Care. The Surgical segment offers equipment, instrumentation, intraocular lenses (IOLs), and other consumables for cataract, refractive, and vitreoretinal surgery. The Vision Care segment provides contact lenses, lens care products, and ocular health products for various eye conditions. Alcon's products are used by eye care professionals and patients worldwide, addressing a wide range of vision needs.

Is ALC stock worth researching?

Alcon's stock presents a mixed picture for potential investors. The company's strong market position, diverse product portfolio, and commitment to innovation are positive indicators. With a market cap of $38.99B and a 10.3% profit margin, Alcon demonstrates financial stability. However, the P/E ratio of 37.13 suggests a relatively high valuation. Growth catalysts, such as new product launches and expansion into emerging markets, could drive future stock appreciation. Investors should carefully consider Alcon's valuation, growth potential, and risk factors before making an investment decision.

What are the main risks for ALC?

Alcon faces several risks inherent to the healthcare industry. Product recalls or safety concerns could significantly damage the company's brand reputation and financial performance. Changes in healthcare regulations, particularly regarding product approvals and reimbursement policies, could negatively impact Alcon's ability to bring new products to market and generate revenue. Intense competition from established and emerging players in the eye care market could erode Alcon's market share. Economic downturns could reduce consumer spending on vision care products, affecting Alcon's sales. Finally, intellectual property infringement and patent disputes pose an ongoing threat to Alcon's competitive advantage.

What are the key factors to evaluate for ALC?

Alcon Inc. (ALC) currently holds an AI score of 51/100, indicating moderate score. The stock trades at a P/E of 38.6x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Analysts target $91.80 (+25% from $73.44). Key strength: Leading market position in both surgical and vision care. Primary risk to monitor: Product recalls or safety concerns impacting brand reputation. This is not financial advice.

How frequently does ALC data refresh on this page?

ALC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ALC's recent stock price performance?

Recent price movement in Alcon Inc. (ALC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $91.80 implies 25% upside from here. Notable catalyst: Leading market position in both surgical and vision care. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ALC overvalued or undervalued right now?

Determining whether Alcon Inc. (ALC) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 38.6. Analysts target $91.80 (+25% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ALC?

Before investing in Alcon Inc. (ALC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Financial metrics are as of the latest available data and may not reflect current performance.
  • Investment decisions should be based on individual risk tolerance and financial circumstances.
Data Sources

Popular Stocks